T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2

An isolated antibody, or antigen-binding fragment thereof, comprising one of:

• (A) (i) a heavy chain (HC) variable region comprising HC-CDR1, HC-CDR2 and HC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 2, 3, and 4;
• and a light chain (LC) variable region comprising LC-CDR1, LC-CDR2 and LC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 8, 9 and 10;
• (ii) a heavy chain (HC) variable region comprising HC-CDR1, HC-CDR2 and HC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 20, 21 and 22;
• and a light chain (LC) variable region comprising LC-CDR1, LC-CDR2 and LC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 26, 27 and 28;
• (iii) a heavy chain (HC) variable region comprising HC-CDR1, HC-CDR2 and HC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 38, 39 and 40;
• and a light chain (LC) variable region comprising LC-CDR1, LC-CDR2 and LC-CDR3 respectively, comprising amino acid sequences selected from SEQ ID NOS:
• 44, 45 and 46;
• (iv) a heavy chain (HC) variable region comprising HC-CDR1, HC-CDR2 and HC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 56, 57 and 58;
• and a light chain (LC) variable region comprising LC-CDR1, LC-CDR2 and LC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 62, 63 and 64;
• (v) a heavy chain (HC) variable region comprising HC-CDR1, HC-CDR2 and HC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 74, 75 and 76;
• and a light chain (LC) variable region comprising LC-CDR1, LC-CDR2 and LC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 80, 81 and 82;
• or
• (vi) a heavy chain (HC) variable region comprising HC-CDR1, HC-CDR2 and HC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 92, 93 and 94;
• and a light chain (LC) variable region comprising LC-CDR1, LC-CDR2 and LC-CDR3 respectively, comprising amino acid sequences SEQ ID NOS:
• 98, 99 and 100;
• or
• (B) a VH and VL comprising first and second amino acid sequences, respectively, selected from SEQ ID NOS:
• 14 and 16;
• 32 and 34;
• 50 and 52;
• 68 and 70;
• 86 and 88;
• and 104 and 106;
• or
• (C) an amino acid sequence selected from SEQ ID NOS:
• 18, 36, 54, 72, 90, and 108;
• wherein the antibody comprises a constant region that has been modified to reduce glycosylation relative to an unmodified antibody.